Chronic aspirin therapy for the prevention of cardiovascular events: A waste of time, or worse?

Nature Clinical Practice Cardiovascular Medicine

Volumn 3, Issue 5, 2006, Pages 234-235

  Cleland, John G F ^a  

^a UNIVERSITY OF HULL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTIBIOTIC AGENT; ATENOLOL; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; FIBRINOLYTIC AGENT;

ANEMIA; ANGINA PECTORIS; ANTICOAGULANT THERAPY; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC DRUG ADMINISTRATION; CLINICAL TRIAL; DISABILITY; DRUG ANTAGONISM; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DYSPEPSIA; EVIDENCE BASED MEDICINE; GASTROINTESTINAL HEMORRHAGE; HEART REINFARCTION; HIGH RISK PATIENT; HUMAN; META ANALYSIS; MORTALITY; NEPHROTOXICITY; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW; SECONDARY PREVENTION; SHORT COURSE THERAPY; STROKE; SYSTEMATIC REVIEW;

ASPIRIN; CARDIOVASCULAR DISEASES; DRUG ADMINISTRATION SCHEDULE; HUMANS; PLATELET AGGREGATION INHIBITORS; TREATMENT OUTCOME;

EID: 33646241541     PISSN: 17434297     EISSN: 17434300     Source Type: Journal    
DOI: 10.1038/ncpcardio0540     Document Type: Review

References (10)

1. Swedberg K et al. (2005) Guidelines for the diagnosis and treatment of Chronic Heart Failure. Eur Heart J 26: 1115-1140
2. Cleland JGF (2002) Is aspirin 'The Weakest Link' in cardiovascular prophylaxis? The surprising lack of evidence supporting the use of aspirin for cardiovascular disease. Prog Cardiovasc Dis 44:275-292
3. ISIS-1 Collaborative Group (1986) Randomised trial of intravenous atenolol among 16,027 cases of suspected acute myocardial infarction: ISIS-1. Lancet 2: 57-66
4. ISIS-2 Collaborative group (1988) Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction. Lancet 2: 349-360
5. Cleland JGF et al. (1995) Is aspirin safe for patients with heart failure? Br Heart J 74: 215-219
6. Antiplatelet Trialists' Collaboration (1988) Secondary prevention of vascular disease by prolonged antiplatelet treatment. BMJ 296: 320-331
7. Antithrombotic Trialists' Collaboration (2002) Collaborative meta-analysis of randomised trials of antiplatelet therapy for the prevention of death, myocardial infarction and stroke in high risk patients. BMJ 324: 71-86
8. Davie AP. et al. (2000) Even low-dose aspirin inhibits arachidonic acid-induced vasodilatation in heart failure. Clin Pharm Ther 67: 530-537
9. Nelson MR et al. (2005) Epidemiological modelling of routine use of low dose aspirin for the primary prevention of coronary heart disease and stroke in those aged >70. BMJ 330: 1306
10. Morant SV et al. (2004) Cardiovascular prophylaxis with aspirin: Costs of supply and management of upper gastrointestinal and renal toxicity. Br J Clin Pharmacol 57: 188-198